Miroslava Rabajdova1, Peter Urban1, Ivana Spakova1, Ladislav Saksun2, Rastislav Dudic3, Alexander Ostro3, Martin Caprnda4, Peter Kruzliak5,6, Mariusz Adamek7, Maria Marekova8. 1. Department of Medical and Clinical Biochemistry, Faculty of Medicine, Pavol Jozef Safarik University, Trieda SNP 1, 040 11, Kosice, Slovakia. 2. Department of Pathology, Saca Hospital, Kosice, Slovakia. 3. Department of Gynecology and Obstetrics, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia. 4. 2nd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia. 5. Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho tr. 1946/1, 612 42, Brno, Czech Republic. kruzliakpeter@gmail.com. 6. 2nd Department of Surgery, Faculty of Medicine, Masaryk University, Brno, Czech Republic. kruzliakpeter@gmail.com. 7. Department of Thoracic Surgery, Medical University of Silesia, Zabrze, Poland. 8. Department of Medical and Clinical Biochemistry, Faculty of Medicine, Pavol Jozef Safarik University, Trieda SNP 1, 040 11, Kosice, Slovakia. maria.marekova@upjs.sk.
Abstract
BACKGROUND: This study describes the effect of rapid tumor growth of patients suffering from various grades of malignant ductal breast carcinoma associated with the gene expression of ECM protein emilin 1, in correlation with the number of gene copies of emilin 1 and degradation of tumor tissue proteins. METHODS: A total of 40 examined patients participated in the experiment (controls, n = 10, grades GI-GIII, each n = 10). After isolation of total mRNA, transcription of mRNA into the cDNA was performed. Quantification of gene expression changes was detected by the real-time PCR method. Analysis at the protein level was performed via Western blot method. RESULTS: During the detection of changes at the mRNA level, a significantly decreased level of emilin 1 in tumor tissues with grade II (about 54 ± 8 % lower than control) was identified. Protein-level analysis indicated an increased level of emilin 1 in tumors with grade I in comparison with control samples (about 10 ± 3 %). CONCLUSION: Obtained results demonstrated that the suppressive role of emilin 1 is related to the grade of growing breast tumors, and associated with increased hypoxia in the tumor microenvironment followed by elevated unfolding and degradation of tissue proteins.
BACKGROUND: This study describes the effect of rapid tumor growth of patients suffering from various grades of malignant ductal breast carcinoma associated with the gene expression of ECM protein emilin 1, in correlation with the number of gene copies of emilin 1 and degradation of tumor tissue proteins. METHODS: A total of 40 examined patients participated in the experiment (controls, n = 10, grades GI-GIII, each n = 10). After isolation of total mRNA, transcription of mRNA into the cDNA was performed. Quantification of gene expression changes was detected by the real-time PCR method. Analysis at the protein level was performed via Western blot method. RESULTS: During the detection of changes at the mRNA level, a significantly decreased level of emilin 1 in tumor tissues with grade II (about 54 ± 8 % lower than control) was identified. Protein-level analysis indicated an increased level of emilin 1 in tumors with grade I in comparison with control samples (about 10 ± 3 %). CONCLUSION: Obtained results demonstrated that the suppressive role of emilin 1 is related to the grade of growing breast tumors, and associated with increased hypoxia in the tumor microenvironment followed by elevated unfolding and degradation of tissue proteins.
Entities:
Keywords:
Breast cancer; Gene expression; Hypoxia; Metastases; Tumor microenvironment
Authors: Karolina Edlund; Cecilia Lindskog; Akira Saito; Anders Berglund; Fredrik Pontén; Hanna Göransson-Kultima; Anders Isaksson; Karin Jirström; Maria Planck; Leif Johansson; Mats Lambe; Lars Holmberg; Fredrik Nyberg; Simon Ekman; Michael Bergqvist; Per Landelius; Kristina Lamberg; Johan Botling; Arne Ostman; Patrick Micke Journal: Int J Cancer Date: 2012-04-24 Impact factor: 7.396
Authors: S Christian; H Ahorn; M Novatchkova; P Garin-Chesa; J E Park; G Weber; F Eisenhaber; W J Rettig; M C Lenter Journal: J Biol Chem Date: 2001-09-14 Impact factor: 5.157
Authors: Chien-hung Tseng; Thomas C Weinacht; Anna E Rhoades; Matthew Murray; Brett J Pearson Journal: Opt Express Date: 2011-11-21 Impact factor: 3.894
Authors: Kelley E McQueeney; Joseph M Salamoun; Jennifer G Ahn; Paula Pekic; Isabella K Blanco; Heather L Struckman; Elizabeth R Sharlow; Peter Wipf; John S Lazo Journal: FASEB J Date: 2018-05-10 Impact factor: 5.191
Authors: Alan R F Godwin; Mukti Singh; Michael P Lockhart-Cairns; Yasmene F Alanazi; Stuart A Cain; Clair Baldock Journal: Matrix Biol Date: 2019-06-18 Impact factor: 11.583
Authors: Andrew Prendergast; Bulat A Ziganshin; Dimitra Papanikolaou; Mohammad A Zafar; Stefania Nicoli; Sandip Mukherjee; John A Elefteriades Journal: Genes (Basel) Date: 2022-01-10 Impact factor: 4.096